Gilead Sciences Announces Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Gilead Sciences (GILD) Tops Q3 EPS by 16c, Remdesivir Revenue $873M in Qtr; Lowers FY EPS Guidance
October 28, 2020 4:04 PM EDTGilead Sciences (NASDAQ: GILD) reported Q3 EPS of $2.11, $0.16 better than the analyst estimate of $1.95. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $6.39 billion. Veklury (remdesivir) revenues were $873 million for the third quarter.
The recent acquisition of Immunomedics has effectively transformed Gileads growth story. Building on the foundation of our strong core business, which proved its durability once again this quarter, we have now significant opportunity to drive additional growth at an accelerated pace, said Daniel ODay, Chairman and Chief Executive Officer, Gilead Sciences. Trodelvy, an approved medicine with... More
